Oncology News | pharmaphorum

News

NICE backs NHS use of Takeda’s Adcetris for rare blood cance...

Takeda’s antibody-drug conjugate Adcetris can now be routinely available on the NHS to patients with a rare form of non-Hodgkin lymphoma (NHL), says NICE.

News

Kiadis Pharma and Sanofi to unlock power of natural killer c...

Sanofi has struck an exclusive rights deal with Dutch biotech Kiadis focused on combining modified natural killer cells with the French pharma’s blood cancer antibody Sarcl

News

EU regulators approve AstraZeneca's Lynparza in pancreatic c...

The European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) in pancreatic cancer patients with a certain mutation.

News

AI health record scanning could identify pancreatic cancer e...

Artificial intelligence (AI) could hold the key to identifying people at risk of pancreatic cancer early, allowing them to start potentially life-saving treatment more quickly.

News

FDA approves Pfizer/Merck KGaA's Bavencio in first line blad...

The FDA has approved Pfizer and Merck KGaA’s immunotherapy Bavencio (avelumab) as a first line maintenance therapy in bladder cancer, setting up a rivalry with alternatives from Roche and A

News

Merck & Co's Keytruda gets new colorectal cancer use after m...

It’s barely a month since Merck & Co unveiled trial results showing that cancer immunotherapy Keytruda (pembrolizumab) works in colorectal cancer patients with certain mutations, and th

NICE backs NHS use of Takeda’s Adcetris for rare blood cance...

Kiadis Pharma and Sanofi to unlock power of natural killer c...

EU regulators approve AstraZeneca's Lynparza in pancreatic c...

AI health record scanning could identify pancreatic cancer e...

FDA approves Pfizer/Merck KGaA's Bavencio in first line blad...

Merck & Co's Keytruda gets new colorectal cancer use after m...

Third Rock in $2bn drug-hunting pact with China's Funnel

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks